DE3779221D1
(de)
*
|
1986-08-19 |
1992-06-25 |
Genentech Inc |
Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
US6582728B1
(en)
*
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
US5661125A
(en)
*
|
1992-08-06 |
1997-08-26 |
Amgen, Inc. |
Stable and preserved erythropoietin compositions
|
US6012450A
(en)
*
|
1993-01-29 |
2000-01-11 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
AU689217B2
(en)
|
1994-03-07 |
1998-03-26 |
Novartis Ag |
Methods and compositions for pulmonary delivery of insulin
|
US6051256A
(en)
*
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
CN1073119C
(zh)
|
1994-05-18 |
2001-10-17 |
吸入治疗系统公司 |
干扰素干粉配方的方法及组合物
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US6586006B2
(en)
|
1994-08-04 |
2003-07-01 |
Elan Drug Delivery Limited |
Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
|
IL116085A
(en)
*
|
1994-12-16 |
1999-12-31 |
Ortho Pharma Corp |
Spray dried erythropoietin
|
US6485726B1
(en)
*
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
AU5710896A
(en)
|
1995-03-31 |
1996-10-16 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
US6136346A
(en)
*
|
1995-04-14 |
2000-10-24 |
Inhale Therapeutic Systems |
Powdered pharmaceutical formulations having improved dispersibility
|
DE69637473T2
(de)
|
1995-06-07 |
2009-05-07 |
Glaxo Group Ltd., Greenford |
An einem thrombopoietin rezeptor bindende peptide und zusammensetzungen
|
US5869451A
(en)
|
1995-06-07 |
1999-02-09 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
DE19539574A1
(de)
*
|
1995-10-25 |
1997-04-30 |
Boehringer Mannheim Gmbh |
Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
|
US5875776A
(en)
*
|
1996-04-09 |
1999-03-02 |
Vivorx Pharmaceuticals, Inc. |
Dry powder inhaler
|
AU724503B2
(en)
*
|
1996-04-29 |
2000-09-21 |
Dura Pharmaceuticals, Inc. |
Methods of dry powder inhalation
|
US7091311B2
(en)
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
GB9612297D0
(en)
*
|
1996-06-11 |
1996-08-14 |
Minnesota Mining & Mfg |
Medicinal aerosol formulations
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
DE19733651A1
(de)
*
|
1997-08-04 |
1999-02-18 |
Boehringer Ingelheim Pharma |
Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
AU757153B2
(en)
†
|
1997-09-29 |
2003-02-06 |
Novartis Ag |
Stabilized preparations for use in metered dose inhalers
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
JP2002512039A
(ja)
*
|
1998-04-22 |
2002-04-23 |
コーネル リサーチ ファンデーション インク. |
イヌエリスロポエチン遺伝子および組換えタンパク質
|
US6696411B1
(en)
*
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
PL360581A1
(en)
|
1999-05-11 |
2004-09-06 |
Ortho-Mcneil Pharmaceutical, Inc. |
Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
|
US20030190644A1
(en)
|
1999-10-13 |
2003-10-09 |
Andreas Braun |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
ATE364689T1
(de)
|
1999-11-18 |
2007-07-15 |
Dendreon Corp |
Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
|
HUP0204136A3
(en)
*
|
1999-12-30 |
2005-09-28 |
Chiron Corp Emeryville |
Methods for pulmonary delivery of interleukin-2
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
WO2001085136A2
(en)
|
2000-05-10 |
2001-11-15 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
HU230874B1
(hu)
*
|
2000-05-15 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Pegilezett humán eritropoietin-fehérjét tartalmazó, szobahőmérsékleten stabil folyékony gyógyászati készítmények
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
KR100587237B1
(ko)
*
|
2000-11-29 |
2006-06-07 |
이토햄 가부시키가이샤 |
분말제제 및 그의 제조방법
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
CA2437333A1
(en)
*
|
2001-02-02 |
2002-08-22 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
|
US20030072717A1
(en)
*
|
2001-02-23 |
2003-04-17 |
Vapotronics, Inc. |
Inhalation device having an optimized air flow path
|
AU2002305052A1
(en)
|
2001-03-13 |
2002-09-24 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
GB0107106D0
(en)
*
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
JP2004535166A
(ja)
|
2001-03-22 |
2004-11-25 |
デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー |
セリンプロテアーゼcvsp14をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
|
EP1389137B1
(de)
*
|
2001-05-21 |
2006-07-19 |
InJet Digital Aerosols Limited |
Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg
|
EG24184A
(en)
*
|
2001-06-15 |
2008-10-08 |
Otsuka Pharma Co Ltd |
Dry powder inhalation system for transpulmonary
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
JP2005514393A
(ja)
|
2001-12-19 |
2005-05-19 |
ネクター セラピューティクス |
アミノグリコシドの肺への供給
|
WO2003055526A2
(en)
*
|
2001-12-21 |
2003-07-10 |
Maxygen Aps |
Erythropoietin conjugates
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
AU2003228809A1
(en)
|
2002-05-03 |
2003-11-17 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof, and related methods
|
US20040009908A1
(en)
*
|
2002-07-10 |
2004-01-15 |
Stamler Jonathan S. |
Methods for treating or preventing ischemic injury
|
DE10234165B4
(de)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
|
DE10234192B4
(de)
*
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
AU2003275077B2
(en)
|
2002-09-18 |
2010-02-04 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods of increasing platelet and hematopoietic stem cell production
|
EP1852441B1
(de)
|
2002-09-24 |
2012-03-28 |
The Burnham Institute |
Mittel zur Modulierung der EPH-Rezeptor-Aktivität
|
CA2547531C
(en)
*
|
2002-11-26 |
2013-11-12 |
Seacoast Neuroscience, Inc. |
Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
|
US20040132645A1
(en)
*
|
2003-01-03 |
2004-07-08 |
Knox Susan J. |
Methods for modulating effects of radiation in a subject
|
EP1596854A4
(de)
|
2003-02-14 |
2007-06-06 |
Childrens Hosp & Res Ct Oak |
Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase
|
CA2521979A1
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
DE102004063927A1
(de)
*
|
2004-01-23 |
2005-12-15 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
US7714114B2
(en)
*
|
2005-02-16 |
2010-05-11 |
Nektar Therapeutics |
Conjugates of an EPO moiety and a polymer
|
US8340944B2
(en)
|
2005-11-30 |
2012-12-25 |
The Invention Science Fund I, Llc |
Computational and/or control systems and methods related to nutraceutical agent selection and dosing
|
US8000981B2
(en)
|
2005-11-30 |
2011-08-16 |
The Invention Science Fund I, Llc |
Methods and systems related to receiving nutraceutical associated information
|
US7927787B2
(en)
|
2006-06-28 |
2011-04-19 |
The Invention Science Fund I, Llc |
Methods and systems for analysis of nutraceutical associated components
|
US20080103746A1
(en)
|
2005-11-30 |
2008-05-01 |
Searete Llc, A Limited Liability Corporation |
Systems and methods for pathogen detection and response
|
US8297028B2
(en)
|
2006-06-14 |
2012-10-30 |
The Invention Science Fund I, Llc |
Individualized pharmaceutical selection and packaging
|
US7827042B2
(en)
|
2005-11-30 |
2010-11-02 |
The Invention Science Fund I, Inc |
Methods and systems related to transmission of nutraceutical associated information
|
US10296720B2
(en)
|
2005-11-30 |
2019-05-21 |
Gearbox Llc |
Computational systems and methods related to nutraceuticals
|
US7974856B2
(en)
|
2005-11-30 |
2011-07-05 |
The Invention Science Fund I, Llc |
Computational systems and methods related to nutraceuticals
|
TW200810773A
(en)
*
|
2006-04-19 |
2008-03-01 |
Alba Therapeutics Corp |
Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
|
JP4546578B2
(ja)
|
2006-07-05 |
2010-09-15 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
|
EP2425819A1
(de)
|
2007-02-11 |
2012-03-07 |
MAP Pharmaceuticals Inc |
Verfahren zur therapeutischen Verabreichung von DHE zur schnellen Linderung von Migräne bei gleichzeitiger Minimierung von Nebenwirkungsprofilen
|
HUE051137T2
(hu)
|
2008-08-14 |
2021-03-01 |
Acceleron Pharma Inc |
GDF-csapdák
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
BR122019023174B1
(pt)
*
|
2011-10-17 |
2021-02-23 |
Acceleron Pharma, Inc |
Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia
|
KR101855242B1
(ko)
|
2012-01-26 |
2018-05-09 |
크리스토퍼 제이. 소레스 |
펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
WO2015136527A1
(en)
|
2014-03-10 |
2015-09-17 |
Health Corporation - Rambam |
Heparanase inhibitory peptides and use thereof for treating clinical pathologies
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
KR102657418B1
(ko)
|
2016-09-02 |
2024-04-15 |
크리스토퍼 제이 소레스 |
신경 보호 및 신경 질환에서의 cgrp 수용체 길항제의 용도
|
AU2018306329A1
(en)
|
2017-07-26 |
2020-02-13 |
Janssen Pharmaceutica Nv |
Methods of protecting vascular integrity induced by targeted radiation therapy
|
MX2021008928A
(es)
|
2019-01-25 |
2021-11-04 |
Janssen Pharmaceutica Nv |
Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
|
JP2022523295A
(ja)
|
2019-01-25 |
2022-04-22 |
ヤンセン ファーマシューティカ エヌ.ベー. |
発疱剤および苛性ガスの毒性作用を緩和する方法
|
MA54820A
(fr)
|
2019-01-25 |
2021-12-01 |
Janssen Pharmaceutica Nv |
Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
|
WO2020201038A1
(en)
|
2019-03-29 |
2020-10-08 |
Pieris Pharmaceuticals Gmbh |
Inhaled administration of lipocalin muteins
|
WO2021019102A2
(en)
|
2019-08-01 |
2021-02-04 |
Acm Biolabs Pte Ltd |
A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
|
EP4138899A2
(de)
|
2020-04-24 |
2023-03-01 |
ACM Biolabs Pte Ltd |
Impfstoff gegen humane pathogene coronaviren
|
AU2021396659A1
(en)
|
2020-12-11 |
2023-05-04 |
Acm Biolabs Pte Ltd |
Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
|
CN117597109A
(zh)
|
2021-02-02 |
2024-02-23 |
Acm 生物实验室私人有限公司 |
聚合物囊泡相关联的佐剂用于刺激免疫应答的单独使用
|
JP2024515564A
(ja)
|
2021-04-08 |
2024-04-10 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
結合組織増殖因子(ctgf)に特異的な新規リポカリンムテイン
|
CA3234340A1
(en)
|
2021-10-01 |
2023-04-06 |
Janssen Pharmaceutica N.V. |
Methods of increasing progenitor cell production
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|